Investigational Drug Information for Clazakizumab
✉ Email this page to a colleague
What is the drug development status for Clazakizumab?
Clazakizumab is an investigational drug.
There have been 14 clinical trials for Clazakizumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 14th 2019.
The most common disease conditions in clinical trials are COVID-19, Infection, and Infections. The leading clinical trial sponsors are CSL Behring, Vitaeris INC, and Stanley Jordan, MD.
There are four US patents protecting this investigational drug and twenty-nine international patents.
Summary for Clazakizumab
| US Patents | 4 |
| International Patents | 29 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-10-14) |
| Vendors | 0 |
Recent Clinical Trials for Clazakizumab
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection | Ayan Sen | Phase 2 |
| Clazakizumab vs. Placebo - COVID-19 Infection | The Methodist Hospital Research Institute | Phase 2 |
| Clazakizumab vs. Placebo - COVID-19 Infection | The Methodist Hospital System | Phase 2 |
Clinical Trial Summary for Clazakizumab
Top disease conditions for Clazakizumab
Top clinical trial sponsors for Clazakizumab
US Patents for Clazakizumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Clazakizumab | See Plans and Pricing | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | See Plans and Pricing |
| Clazakizumab | See Plans and Pricing | Cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (Eggertsville, NY) | See Plans and Pricing |
| Clazakizumab | See Plans and Pricing | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Clazakizumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Clazakizumab | Argentina | AR108097 | 2036-04-04 | See Plans and Pricing |
| Clazakizumab | Australia | AU2017246228 | 2036-04-04 | See Plans and Pricing |
| Clazakizumab | Brazil | BR112018070214 | 2036-04-04 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
